Clinical trials: PSMA PET/CT
Metastatic Hormone-Sensitive Prostate Cancer, Prostate Cancer
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
This multicenter retrospective study developed and validated a prediction model based on PSMA PET/CT and routine clinical information to estimate early treatment response in patients with metastatic hormone-sensitive prostate…
- Trial name
- NCT07428642
- Testing
- Androgen Deprivation Therapy, Apalutamide, Enzalutamide
- Where
- China
- Volunteers
- 168 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
This clinical trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) works in detecting prostate cancer that has come back (recurrent)…
- Trial name
- NCT02940262
- Testing
- Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography
- Where
- United States
- Volunteers
- 1,138 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer, Lymph Node Metastases
Accuracy of Lymph Node Imaging in Prostate Cancer: PSMA PET-CT and Nano-MRI
Following curative intended therapy in prostate cancer patients, a high proportion of patients (approx. 25%) relapse with local and/or distant recurrence.
- Trial name
- MAGNIFY (NCT03223064)
- Testing
- Ferumoxtran-10 enhanced MRI; MRI contrast agent, 68Ga PSMA PET-CT
- Where
- 3 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
PET/CT, Prostate Specific Membrane Antigen
68Ga-PSMA PET/CT Imaging in Assessment of Prostate Cancer
Dual-time point 68Ga-PSMA PET/CT could increase the lesion detection in PCa patients, it remains difficult to perform in clinical practice.
- Conditions
- PET/CT, Prostate Specific Membrane Antigen, IMAGE
- Trial name
- NCT05134064
- Testing
- total-body PET/CT
- Where
- China
- Volunteers
- 66 people
- Sponsor
- RenJi Hospital
Recurrent Prostate Carcinoma
Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy
This phase III trial studies how well Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET)/computed tomography (CT) works in diagnosing participants with prostate cancer that has come back after…
- Trial name
- PSMA SRT (NCT03582774)
- Testing
- Best Practice, Computed Tomography, Gallium Ga 68-labeled PSMA-11
- Where
- 2 sites in United States
- Volunteers
- 193 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer (Diagnosis), Prostate Cancer Metastatic
Evaluation of the Metastasis and Recurrence of Prostate Cancer
This study aims to use the new molecular probe 18F-PSMA for the diagnosis,staging ,recurrence monitoring and evaluation of the prostate cancer.By compared with the conventional imaging methods (whole body bone scintigraphy and…
- Conditions
- Prostate Cancer (Diagnosis), Prostate Cancer Metastatic, Prostate Cancer Recurrent, Prostate Cancer Stage
- Trial name
- NCT03507595
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Prostatic Neoplasms
Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient
It is a cross sectional study aimed to correlate between PSA Levels and F-18 PSMA PET/CT Scan findings and to evaluate the impact of PET/CT findings on the patient management
- Trial name
- NCT06209853
- Testing
- PSMA PET/CT
- Where
- Egypt
- Volunteers
- 59 people
- Sponsor
- Assiut University
Solid Cancers
68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study
This project aims to monitor the innocuity/safety profile of cyclotron-produced [68Ga]-PSMA-617 PET imaging in PSMA-expressing cancers. It is a single-site, pragmatic, non-randomized and open-label study, with no control group.
- Trial name
- NCT05228106
- Testing
- [68Ga]-PSMA-617
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma
Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases
This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.
- Conditions
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma, Brain Metastases From Breast Cancer
- Trial name
- NCT07511933
- Testing
- 86-Gallium PSMA PET/CT
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer
Pathological Positivity Rate in Prostate Cancer Patients with PI-RADS 4 and First Negative Biopsy
The purpose of this prospective, single-center, single-arm trial was to evaluate the pathologic type of re-treatment based on a clear PI-RADS score of ≥4 with a first negative prostate biopsy, belonging to the high-risk group of…
- Trial name
- NCT06677775
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Anhui Provincial Hospital
Prostate Cancer
PSMA PET/CT vs. mpMRI in Patients With a High Suspicion of Prostate Cancer: a Head to Head, Parallel, Prospective Trial
This is prospective single-arm case-control study designed to compare in parallel PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy ("experimental test") with mpMRI/TRUS fusion prostate biopsy ("standard test") in men…
- Trial name
- PROSPET-BX (NCT05297162)
- Testing
- PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy
- Where
- Italy
- Volunteers
- 128 people
- Sponsor
- Istituto Clinico Humanitas
Prostate Cancer Metastatic Disease, PET / CT
The Prognostic Value of PET/CT for Tumor Progression in Patients With Metastatic Hormone-sensitive Prostate Cancer
Investigators retrospectively collected data from consecutive patients treated at the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, from October 2020 to March 2024.
- Trial name
- NCT06915714
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
This phase II trial evaluates an imaging technique (rhPSMA-7.3 positron emission tomography [PET]/computed tomography [CT]) for detecting prostate cancer in patients who have increasing prostate-specific antigen levels following…
- Trial name
- NCT06813898
- Testing
- Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Prostate Cancer
Robotic-arm Assisted Ga-68 PSMA PET/CT Guided Transgluteal Prostate Biopsy
Gallium-68 prostate-specific-membrane-antigen (Ga-68 PSMA) PET/CT is being used in Prostate cancer imaging. In the present study, we aimed to evaluate the efficacy and safety of robotic arm-assisted Ga-68 PSMA PET/CT-guided…
- Trial name
- NCT05022576
- Testing
- Robotic arm assisted PSMA PET/CT guided prostate biopsy
- Where
- India
- Volunteers
- 78 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Prostate Cancer, Prostate Cancer Metastatic
18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients
To compare the diagnostic performance of 18-F PSMA PET/CT and CT alone in initial staging, assessment of therapy response, as well as evaluation of biochemical recurrence of prostatic cancer patients The main question it aims to…
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent
- Trial name
- NCT07485881
- Volunteers
- 59 people
- Sponsor
- Assiut University